Study design and participants
AD, MAPT
SECONDARY
In this randomized, double-blind, placebo-controlled, multicenter, MAD phase 1b trial with an open-label LTE, we evaluated the safety, PK and target engagement of MAPTEligible participants were between the ages of 50 and 74 years and had mild AD, defined by a CDRMAD part 1 was conducted at 12 centers in Canada, Finland, Germany, the United Kingdom, the Netherlands and Sweden. A centralized automated randomization system assigned participants 3:1 to receive bolus IT injections of MAPTThe primary objective was evaluation of the safety of MAPTThe secondary endpoint was the characterization of the PK of MAPTThe key exploratory endpoint was CSF t-tau concentration. Additional exploratory endpoints included characterization of MAPT